Janssen-Cilag wins extended license to Zytiga in Europe
Licence extension includes the use of Zytiga as a combination therapy along with prednisone or prednisolone to treat metastatic castration-resistant prostate cancer (mCRPC), in men who are asymptomatic
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.